Wellington Management Group LLP Lowers Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Wellington Management Group LLP trimmed its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 13.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,489 shares of the biopharmaceutical company’s stock after selling 3,959 shares during the quarter. Wellington Management Group LLP’s holdings in Agios Pharmaceuticals were worth $838,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Venturi Wealth Management LLC bought a new position in shares of Agios Pharmaceuticals in the 4th quarter worth $33,000. Wingate Wealth Advisors Inc. bought a new position in Agios Pharmaceuticals in the fourth quarter worth about $53,000. KBC Group NV lifted its position in shares of Agios Pharmaceuticals by 30.5% during the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 611 shares during the last quarter. AlphaQuest LLC grew its position in shares of Agios Pharmaceuticals by 106.2% in the 4th quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 2,338 shares during the last quarter. Finally, AlphaCentric Advisors LLC purchased a new position in shares of Agios Pharmaceuticals in the 4th quarter worth approximately $202,000.

Agios Pharmaceuticals Trading Up 5.5 %

Shares of NASDAQ:AGIO opened at $26.70 on Monday. Agios Pharmaceuticals, Inc. has a twelve month low of $23.42 and a twelve month high of $62.58. The company has a market cap of $1.53 billion, a PE ratio of 2.35 and a beta of 0.83. The company’s 50 day moving average is $31.39 and its 200 day moving average is $39.18.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. Equities research analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Agios Pharmaceuticals

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm’s stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the sale, the director now directly owns 149,220 shares of the company’s stock, valued at $3,864,798. This trade represents a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 4.93% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. HC Wainwright assumed coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They set a “buy” rating and a $58.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Finally, StockNews.com cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $56.57.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.